Long-term Outcomes in Patients with Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-Associated Disorder

Sebastian Lopez-Chiriboga; Elia Sechi; Marina Buciuc; John J. Chen; Sean J. Pittock; Claudia F. Lucchinetti; Eoin P. Flanagan

doi:10.1001/jamaneurol.2020.3115

Long-term Outcomes in Patients with Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-Associated Disorder

Sebastian Lopez-Chiriboga, Elia Sechi, Marina Buciuc, John J. Chen, Sean J. Pittock, Claudia F. Lucchinetti, Eoin P. Flanagan

Research output: Contribution to journal › Letter › peer-review

8 Scopus citations

Original language	English (US)
Pages (from-to)	1575-1577
Number of pages	3
Journal	JAMA neurology
Volume	77
Issue number	12
DOIs	https://doi.org/10.1001/jamaneurol.2020.3115
State	Published - Dec 2020

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1001/jamaneurol.2020.3115

Cite this

@article{ec82b14873b5447d9f9d44e799fcf15e,

title = "Long-term Outcomes in Patients with Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-Associated Disorder",

author = "Sebastian Lopez-Chiriboga and Elia Sechi and Marina Buciuc and Chen, {John J.} and Pittock, {Sean J.} and Lucchinetti, {Claudia F.} and Flanagan, {Eoin P.}",

note = "Funding Information: Conflict of Interest Disclosures: Dr Pittock reported receiving grants, personal fees, and nonfinancial support from Alexion Pharmaceuticals; grants from Grifols and the Autoimmune Encephalitis Alliance; grants, personal fees, nonfinancial support, and other from MedImmune; other support from Astellas; and personal fees from UCB; and having Patent No. 8,889,102 (Application No. 12-678350)—Neuromyelitis Optica Autoantibodies as a Marker for Neoplasia— issued; and Patent No. 9,891,219B2 (Application No. 12-573942)—Methods for Treating Neuromyelitis Optica (NMO) by Administration of Eculizumab to an Individual That Is Aquaporin-4 (AQP4)-IgG Autoantibody Positive—issued. Dr Lucchinetti reported receiving grants from Biogen, National Multiple Sclerosis Society, Kingsland Foundation, and National Institute of Neurological Disorders and Stroke during the conduct of the study. Dr Flanagan reported serving as a site principal investigator for a clinical trial of inebilizumab in neuromyelitis optica spectrum disorder and receiving funding to support the research work from Viela Bio during the conduct of the study. No other disclosures were reported. Funding/Support: This work was supported by funding from the National Institutes of Health (R01NS113828).",

year = "2020",

month = dec,

doi = "10.1001/jamaneurol.2020.3115",

language = "English (US)",

volume = "77",

pages = "1575--1577",

journal = "JAMA neurology",

issn = "2168-6149",

publisher = "American Medical Association",

number = "12",

}

TY - JOUR

T1 - Long-term Outcomes in Patients with Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-Associated Disorder

AU - Lopez-Chiriboga, Sebastian

AU - Sechi, Elia

AU - Buciuc, Marina

AU - Chen, John J.

AU - Pittock, Sean J.

AU - Lucchinetti, Claudia F.

AU - Flanagan, Eoin P.

N1 - Funding Information: Conflict of Interest Disclosures: Dr Pittock reported receiving grants, personal fees, and nonfinancial support from Alexion Pharmaceuticals; grants from Grifols and the Autoimmune Encephalitis Alliance; grants, personal fees, nonfinancial support, and other from MedImmune; other support from Astellas; and personal fees from UCB; and having Patent No. 8,889,102 (Application No. 12-678350)—Neuromyelitis Optica Autoantibodies as a Marker for Neoplasia— issued; and Patent No. 9,891,219B2 (Application No. 12-573942)—Methods for Treating Neuromyelitis Optica (NMO) by Administration of Eculizumab to an Individual That Is Aquaporin-4 (AQP4)-IgG Autoantibody Positive—issued. Dr Lucchinetti reported receiving grants from Biogen, National Multiple Sclerosis Society, Kingsland Foundation, and National Institute of Neurological Disorders and Stroke during the conduct of the study. Dr Flanagan reported serving as a site principal investigator for a clinical trial of inebilizumab in neuromyelitis optica spectrum disorder and receiving funding to support the research work from Viela Bio during the conduct of the study. No other disclosures were reported. Funding/Support: This work was supported by funding from the National Institutes of Health (R01NS113828).

PY - 2020/12

Y1 - 2020/12

UR - http://www.scopus.com/inward/record.url?scp=85090359336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090359336&partnerID=8YFLogxK

U2 - 10.1001/jamaneurol.2020.3115

DO - 10.1001/jamaneurol.2020.3115

M3 - Letter

C2 - 32865549

AN - SCOPUS:85090359336

SN - 2168-6149

VL - 77

SP - 1575

EP - 1577

JO - JAMA neurology

JF - JAMA neurology

IS - 12

ER -

Long-term Outcomes in Patients with Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-Associated Disorder

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this